Evidence map›Paper›PMID 29033540›Full record

ArticleDrug design, development and therapy2017

Assay development and high-throughput screening for small molecule inhibitors of a

Laura Stanbery, Jyl S Matson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Laura StanberyDepartment of Medical Microbiology and Immunology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA.
Jyl S MatsonDepartment of Medical Microbiology and Immunology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA.
University of Toledo · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Identification of novel inhibitors of a Vibrio cholerae stress response pathwayR01HD075928 · NICHD · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MATSON, JYL S · 2013 to 2015
$743k
NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR002240NICHD NIH HHS R01 HD075928
6 · The paper itself

Abstract

Antibiotics are important adjuncts to oral rehydration therapy in cholera disease management. However, due to the rapid emergence of resistance to the antibiotics used to treat cholera, therapeutic options are becoming limited. Therefore, there is a critical need to develop additional therapeutics to aid in the treatment of cholera. Previous studies showed that the extracytoplasmic stress response (σ

Indexed as

Drug Evaluation, PreclinicalHigh-Throughput Screening AssaysVibrio choleraeVirulencehigh-throughput screeningstress responseVibrio choleraeσE

Identifiers

PMID29033540
PMCPMC5614740
OpenAlexW2756344172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.